Orion published Financial Statement Release for 2019 on Wednesday, 5 February 2020. The release, presentation material and link to live webcast recording are available here.
Orion Group's Financial Statement documents for 2019 are available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.
From the sustainability section you will find, among others, our Sustainability reports, Code of Conduct and Quality Policy.
